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Virtual reality stimulation to reduce the
incidence of delirium in critically ill
patients: study protocol for a randomized
clinical trial
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Abstract
Background: Delirium has been long considered as a major contributor to cognitive impairments and increased
mortality following a critical illness. Pharmacologic and non-pharmacologic strategies are used against delirium in
the intensive care unit (ICU), despite these strategies remaining controversial. Previous studies have shown the
feasibility of using virtual reality within the ICU setting, and we propose to use this technology to investigate the
effect of immersive virtual reality stimulation on the incidence of delirium in the ICU. Moreover, we propose to use
motion sensors to determine if patient movement patterns can lead to early prediction of delirium onset.
Methods: This study is conducted as a randomized clinical trial. A total of 920 critically ill patients in the ICU will
participate. The control group will receive standard ICU care, whereas the intervention group will, in addition to the
standard ICU care, receive relaxing 360-degree immersive virtual reality content played inside a head-mounted
display with noise-cancelling headphones, three times a day. The first 100 patients, regardless of their group, will
additionally have their movement patterns recorded using wearable and ambient sensors. Follow-up measurements
will take place 6 months after discharge from the ICU.
Discussion: Delirium is widely present within the ICU setting but lacks validated prevention and treatment
strategies. By providing patients with virtual reality stimulation presented inside a head-mounted display and noise-
cancelling headphones, participants may be isolated from disturbances on an ICU. It is believed that by doing so,
the incidence of delirium will be decrease among these patients. Moreover, identifying movement patterns
associated with delirium would allow for early detection and intervention, which may further improve long-term
negative outcomes associated with delirium during critical care.
Trial registration: ClinicalTrials.gov NCT04498585. Registered on August 3, 2020
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Introduction
Background and rationale {6a}
Critically ill patients in the intensive care unit (ICU)
frequently develop delirium. The prevalence of delirium
in the ICU is between 35 and 80% in ventilated and
non-ventilated patients [1, 2]. Delirium is defined as a
disturbance in attention, awareness, and cognition with
reduced ability to direct, focus, sustain, and shift atten-
tion, and reduced orientation to the environment [3, 4].
It profoundly affects both the patients and their families
as it is associated with increased mortality [1, 5, 6],
increased cognitive impairment [1, 5], longer duration of
mechanical ventilation [1, 6, 7], unplanned extubation
and catheter removal by the patient [6, 7], and longer
ICU and hospital stay [1, 5–7]. Furthermore, it has been
shown that the duration of delirium is associated with
worse long-term cognitive impairment [8]. Delirium may
occur as a hypoactive, hyperactive, or mixed form. Un-
fortunately, delirium often evades diagnosis as it most
frequently presents with hypoactivity and somnolence
[3]. Conversely, it can be more easily recognized when
patients are hyperactive or agitated [3].
In prevention and treatment, pharmacological and
non-pharmacological strategies are discussed [5].
Pharmacologic prevention and treatment of delirium re-
mains controversial [5, 9, 10]. Despite this, in hyper-
active patients, pharmacological measures are used in
the clinical setting, with typical and atypical antipsy-
chotics and dexmedetomidine recommended for con-
trolling the symptoms [9]. In the Clinical Practice
Guidelines for adult patients in the ICU, Devlin et al. do
not recommend the use of haloperidol, atypical antipsy-
chotics, or statins, for treating delirium except in pa-
tients experiencing distress, or showing signs of agitation
or hallucinations, unrelated to the delirium [5]. All three
drugs were not found to decrease delirium duration,
duration of mechanical ventilation, ICU length of stay,
or mortality [5]. Similarly to haloperidol, the effective-
ness of dexmedetomidine in patients with delirium
without agitation, or with agitation not related to being
mechanically ventilated, remains unclear [5].
Despite non-pharmacological strategies also lacking
clinical evidence of their efficacy, single- or multicompo-
nent interventions, such as early mobilization, sleep
improvement, and reorientation, are often used for
preventing or treating delirium [5, 11]. One advantage of
using multicomponent strategies, as opposed to single
component approaches, proposed in the literature, is
that multicomponent strategies may target more than
one risk factor for delirium simultaneously [12]. In this
way, there is a greater potential of having a beneficial ef-
fect, even in the absence of strict compliance.
In a pilot study, Gerber et al. [13] showed the feasibility,
usability, and acceptance of virtual reality (VR)
stimulation (i.e. relaxing nature videos) as a new non-
pharmacological intervention to comfort patients during
their stay in the ICU. Currently, head-mounted displays
have been widely used therapeutically in individuals with
various mental and physical disorders [14–16]. Two stud-
ies conducted by Gerber et al. [17, 18] produced evidence
that VR stimulation with a head-mounted display in ICU
settings is potentially beneficial for patients. More specific-
ally, the relaxing effect produced by the VR stimulation
has a high potential to reduce the incidence of delirium.
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Furthermore, VR-based cognitive stimulation in critically
ill patients did not evoke any negative reactions and is
thus safe to use in this population [13, 17, 18].
For the two main aims of this randomized clinical trial,
we focus on (1) reducing the incidence of delirium by using
VR stimulation and (2) analysing movement patterns in
order to obtain indicators as to the occurrence of delirium.
Objectives {7}
The primary objective of this randomized clinical trial is
to analyse the effect of VR stimulation on the incidence
of delirium after admission to the ICU. Participants in
the control group will receive the standard ICU care,
while participants in the intervention group will
additionally receive VR stimulation. We hypothesize that
participants receiving the VR stimulation will have a lower
incidence of delirium during their stay in the ICU,
compared to the control group. The secondary objectives
are to evaluate differences in movement patterns and
intensity between the intervention and control groups and
between participants with delirium and without delirium.
We expect that these differences will be related to the
different types of delirium (i.e. hyperactive, hypoactive, or
mixed). Additionally, it is predicted that it will be possible
to detect differences in movement patterns between
groups and identify patterns indicating the presence or
absence of delirium. Secondary objectives also include the
evaluation of the effect of VR on duration of delirium. In
this case, it is hypothesized that the duration of delirium
will be shorter in participants receiving the VR
stimulation compared to those in the control group.
Further objectives which will be addressed include (1)
evaluating the effect of VR stimulation, identified by
changes in physiological parameters; (2) evaluating how
easily the VR stimulation can be provided to patients by
critical care professionals; (3) describing differences in
cognition, health-related quality of life, and functional
independence between groups, using questionnaires; and
(4) evaluating if VR reduces the need for pharmaco-
logical treatment of delirium.
Trial design {8}
This study is conducted as a randomized clinical trial
with a superiority framework and a parallel group
design. There are two distinct groups; the control group
will receive standard ICU care, whereas the intervention
group will, in addition to the standard ICU care, receive
relaxing VR stimulation three times a day.
Methods: participants, interventions, and
outcomes
Study setting {9}
The study will be conducted in the interdisciplinary adult
ICU of the University Hospital of Bern, (Inselspital), a
Swiss university hospital. Data will be recorded solely at
this location.
Eligibility criteria {10}
All patients in the ICU, including patients with acquired
brain injury, are eligible to participate in this study. The
interventions will be performed by trained ICU nurses.
Inclusion criteria
– Aged ≥ 18 years with no upper age limit
– No severe visual or auditory impairments (diplopia,
low vision due to macular degeneration, retinopathy,
severe hypacusis, or deafness)
– Estimated length of stay > 24 h
– Can keep eyes open for at least 30 s
– German or French speaking
Exclusion criteria
– Known psychotic disorders associated with delusions
(e.g. schizophrenia, dementia)
– Recent history of major depression
– Admission for drug overdose
Who will take informed consent? {26a}
All patients who meet the inclusion criteria will be
approached by a member of the study team within 24 h
of ICU admission. However, since patients are often
unable to give consent due to their condition and the
situation of their relatives or authorized representative is
often unclear at the beginning, a neutral physician may
be consulted before the patient is included in the study.
The neutral physician who is not involved in the study
and who safeguards the participant interests provides a
written authorization to enrol the patient.
If a proxy consent is not obtainable because no
relatives and/or representative is identified or the
representative cannot be reasonably contacted, the
patient will stay in the study and their data will be used
in order not to compromise the results of the study.
In the case where the patient is discharged from the
ICU in a state of capacity that does not allow him/her to
provide consent, a re-evaluation of their capacity to con-
sent will only be done during the study follow-up visits
or telephone follow-up calls (6 months visits). If the pa-
tient cannot provide informed consent at 6 months
post-discharge, the relatives and/or representative will
be asked again to provide informed consent to use the
study data.
Informed consent will be obtained by a member of the
study team after providing the patient, family
member(s), or authorized representative with both
verbal and written study information about what the
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study entails (e.g. its benefits, risks, design) and what the
informed consent states. If the patient, family
member(s), or an authorized representative agrees to
participate in the study, they will be asked to sign a
written consent form for their study participation. If a
family member or authorized representative provides
consent on the patients’ behalf, the patient will be asked
directly for their consent as soon as their health
condition allows. The patient will again be asked for
their written informed consent 6 months post-ICU dis-
charge to participate in a 6-month follow-up visit.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Not applicable, all data which will be collected from the
participant is outlined in the informed consent and
would only be used to address the topics listed among
the objectives of this study. Moreover, this trial does not
involve collecting biological specimens for storage.
Interventions
Explanation for the choice of comparators {6b}
In this study, we have chosen to use a control group as a
comparator. The control group is made up of
individuals who are also patients hospitalized in the ICU
and receive the same standard ICU care to address their
health needs as participants in the intervention group,
only without the VR stimulation.
Intervention description {11a}
The intervention for this study consists of relaxing VR
stimulation, which will be started as soon as possible
after obtaining informed consent. As stimulation
material, immersive 360-degree videos (e.g. nature envi-
ronments, animals, urban parks) will be played inside a
commercially available head-mounted display, with the
video sound played inside noise-cancelling headphones.
A single video will be shown during each stimulation
period, with each video lasting 30min in length; how-
ever, the length may be shortened based on individual
participant reaction. The stimulation will be provided
three times per day, morning, midday, and evening,
every day until the patient is discharged from the ICU,
or the maximum of 14 days has been reached. A new
video will be played during each stimulation. A total of
44 videos were filmed. All videos shown on the same
day will depict the same location, but at different time
points. The location shown on a given day is randomly
assigned. Videos filmed in the morning, midday, or
evening will be shown in the morning, midday, or even-
ing, respectively.
The intervention group will also receive standard ICU
care and, if needed, receive treatment for delirium (local
delirium protocol), same as in the control group.
Therapy would include pharmacological agents (e.g.
quetiapin) and non-pharmacological interventions (e.g.
early mobilization, communication tools, sleep improve-
ment, family involvement). The first 100 participants,
regardless of their group, will additionally be equipped
so data can be recorded regarding movement patterns.
Criteria for discontinuing or modifying allocated
interventions {11b}
Participants will be withdrawn from the study if they
voluntarily withdraw informed consent at any time.
Moreover, participation in the study will be discontinued
if:
– There are changes in their health status that makes
continued participation inadvisable
– There are safety concerns
The target length of the intervention is 30 min, but
stimulation can be stopped prior to achieving this goal
per participant request, or perceived negative reaction of
the participant, regardless of the discontinuation criteria
listed above.
Strategies to improve adherence to interventions {11c}
VR stimulation will be provided to the participants by
trained ICU nurses who are part of the study team;
therefore, adherence while in the ICU should be very
high. To ensure adherence at 6 months post-ICU dis-
charge, the participants will be contacted by a member
of the study team. The follow-up visit would also take
place during a standard patient follow-up appointment.
Relevant concomitant care permitted or prohibited
during the trial {11d}
All standard ICU care to treat the participant during
their time in the ICU will be permitted.
Provisions for post-trial care {30}
In the event of study-related damage or injuries, Univer-
sity Hospital Bern (Inselspital) shall provide compensa-
tion, except for claims that arise from misconduct or
gross negligence of involved study personnel.
Outcomes {12}
The primary outcome is delirium incidence, measured
three times a day (morning, midday, and evening) by the
Intensive Care Delirium Screening Checklist (ICDSC) as
part of standard assessment. With the ICDSC, delirium
is determined by consciousness, inattention, disorientation,
hallucination, agitation or retardation, speech and mood,
sleep/wake cycle disturbance, and fluctuation [19]. A
unique incidence of delirium is counted once a patient
reaches a score of ≥ 4, on a scale from 0 to 8 [20]. The
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entire period that a patient has a score ≥ 4 is considered as
a single episode, and accordingly, counts only as a single
incidence. The mean incidences of delirium per group will
be looked at. The incidence of delirium is considered to be
clinically relevant as it is known that patients who
experience delirium while in critical care have worse long-
term outcomes [4]. Furthermore, due to the possible influ-
ence of sedatives and analgesics on the incidence of delir-
ium, both sedation and pain levels will be assessed every
2 h [5]. Consciousness and sedation will be measured using
the Glasgow Coma Scale [21] and the Richmond Agitation
Sedation Scale [22], respectively, and pain will be measured
using the Numeric Rating Scale [23] and the Behavioural
Pain Observation Tool [24].
As a secondary outcome, the duration of delirium will
be evaluated per 8-h periods, or as needed, while pa-
tients are in the ICU. If the participant is assessed as
delirious via the ICDSC during any of the assessments
during an 8-h span, the entire period will count as
delirious. Duration of delirium is clinically relevant
knowing that the duration of delirium is an independ-
ent predictor of mortality 6 and 12 months post-ICU
admission [25, 26].
Additional secondary outcomes include the pattern
and intensity of movements, before and during delirium
as well as between groups, measured continuously
during the ICU stay. The fact that patients in delirium
have fluctuating motor performance movement patterns,
differing from baseline, could be a possible marker for
delirium detection [27]. Therefore, acceleration will be
measured with wearable sensors such as inertial
measurement units, which have been previously used
successfully in the ICU [28]. The monitoring of patients’
movement patterns could provide a means of early
detection of delirium, permitting early intervention by
the care staff.
Other pre-specified outcome variables include physio-
logical parameters, feasibility of using the VR stimulation
by ICU nurses, cognition at ICU discharge and 6 months
post-discharge, health-related quality of life and func-
tional independence before ICU admission and 6 months
post-discharge, disease-related data, and survival
6 months post-discharge from the ICU. Physiological pa-
rameters (e.g. blood pressure, heart rate, respiration rate)
will be recorded continuously and changes from base-
line, or the start of an event such as VR stimulation, will
be compared to later time points. The changes occurring
in these parameters over time, together with disease-
related data, are of interest and could indicate what
effect, if any, VR stimulation has on the condition of the
participant. Scores for health-related quality of life,
functional independence, and clinical frailty before ICU
admission and 6 months post-discharge, and cognition
before ICU discharge and 6 months post-discharge, will
be compared to determine if any significant differences
occur. Additionally, the average survival 6 months post-
ICU discharge will be compared between groups. Look-
ing at these variables between groups is important as
cognition, health-related quality of life, independence,
frailty, and mortality, among others, are known to be
negatively impacted by the presence of delirium during
the time spent in the ICU. Therefore, it is meaningful to
identify if there were any significant changes in these as-
pects for individuals in the treatment group compared
to the controls. It will also be important to determine if
providing such an intervention is feasible for the care
providers. For this, the validated System Usability Scale
will be completed by the nurses in order to understand
if overall, the use of this technology was accepted and
whether or not it could be integrated into standard ICU
care practices [29].
Participant timeline {13}
Participant recruitment, enrolment, and allocation will
all be targeted for the first 24 h following admission to
the ICU. Once admitted, the participants will be
monitored and evaluated, through a series of assessments,
every day they are in the ICU up until their discharge, or
at most, 14 days following ICU admission. A follow-up
visit is planned for 6 months post-ICU discharge (Fig. 1).
Sample size {14}
The sample size calculation is based on testing of the
primary outcome. Based on trials conducted by Boettger
et al. [30] and Bounds et al. [31], we assume that 39%
and 30% of participants will have delirium in the control
and intervention groups, respectively. A total sample
size of 920 participants (460 per group) provides a
power of 80% to detect a significant improvement, and
thereby a decrease, in the proportion of delirium with a
two-sided significance threshold of 0.05. The statistical
power to reject the null hypothesis under the above as-
sumptions is 0.95 and the overall type I error rate is
0.05. However, the prevalence of delirium in the ICU be-
ing reported is between 35 and 80% making it difficult
to calculate an exact power. We will, therefore, conduct
a blinded interim analysis after inclusion of 100 partici-
pants (50 per group); re-estimation and adjustment of
the sample size will be made if necessary.
Recruitment {15}
With approximately 4000 patients [32] admitted yearly
to the ICU at the University Hospital of Bern (Inselspital),
we believe achieving our total sample size of 920
participants over the 3 years for which our study is
planned is feasible. All patients admitted to the ICU will
be screened for inclusion into the study, by either a
registered nurse or a treating physician. Family members
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will be contacted as soon as possible thereafter. Patients
will be recruited every day, including on the weekends.
Assignment of interventions: allocation
Sequence generation {16a}
In the enrolment phase, ICU patients will be randomly
assigned to either the intervention or the control group
with 1:1 allocation, stratified by gender and age. The
randomization will be computer-generated and performed
in the study database using the Research Electronic Data
Capture System (REDCap) (Vanderbilt University, TN,
USA). The research team will not be blinded.
Concealment mechanism {16b}
The allocation sequence will be implemented in the
study database REDCap by an independent data
manager not involved in the analysis of the study. No
other study personnel will have access to the allocation
sequence that is stored in REDCap. Allocation of
individual patients to their respective intervention group
Fig. 1 Schedule of enrolment, intervention, and assessments. Arrows represent continuous measurements, and X’s represent an assessment or
intervention provided at a specific time point. One asterisk indicates that whenever possible, informed consent will be obtained directly from the patient.
If the patient is unable to provide informed consent, we will ask the patients’ relatives and/or an authorized representative for the study consent. Two
asterisks indicate that we will ask the patients’ relatives at the earliest possible date, with questions regarding the week prior to arrival at the ICU
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will be revealed to study personnel after the allocation
has occurred via the web interface of REDCap.
Implementation {16c}
The allocation sequence assigning participants to their
respective group will be computer-generated. The study
team will enrol participants prior to allocation.
Assignment of interventions: blinding
Who will be blinded {17a}
The research team will not be blinded after assignment
to interventions, nor will any member of the
interprofessional team be blinded when carrying out the
intervention. However, an independent statistician who
will be conducting the interim analysis will be blinded.
Additionally, the analysis of the primary outcome of
incidence of delirium, and secondary outcome looking at
the duration of delirium, will be done blinded.
Procedure for unblinding if needed {17b}
Only one person, the independent statistician, is blinded
during the intervention period of this study. If required,
unblinding could occur after the interim analysis has
been conducted.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The study starts within 24 h after admission to the ICU.
In the enrolment phase, participants will be randomly
assigned to either the intervention or the control group,
with the intervention beginning as soon as possible
following enrolment. Three times a day (between 7:00
am and 7:00 pm) for 30 min, participants in the
intervention group will receive the intervention (VR
stimulation) applied directly in the bed. The intervention
will be included in the daily schedule of the patients.
The intervention period ends when the patient is
discharged from the ICU or at the latest 14 days after
admission to the ICU. Thus, the intervention period
depends on the length of stay in the ICU and can vary
between participants.
After allocation, incidence and duration of delirium is
assessed in three shifts a day. If delirium is diagnosed,
the standard ICU delirium therapy (local delirium
protocol) will be started, regardless of the participants’
group. VR stimulation will optimally start before this
time point. Delirium is assessed using the ICDSC which
is a reliable (Cohen’s kappa (κ) = 0.60) [33] and specific
(95%) [33] tool to detect delirium in ICU patients [5]
and was translated into German by Radtke et al. [34]
Assessment of sedation will be done using the
Richmond Agitation Sedation Scale which has a
reliability of κ = 0.91 and a face validity with 81–92%
agreement [22, 35]. Consciousness will be evaluated
according to the Glasgow Coma Score which was
originally found to have a κ = 0.66–0.77 for the whole
scale, but has since been found to have higher reliability
when looking at the eye, motor, and verbal scales
individually (κ = 0.89, 0.94, and 0.88, respectively) [21,
36]. The validity for the Glasgow Coma Scale, however,
remains controversial with some stating that the validity
has been well established [37], while others question
how the scale is assessed under different conditions such
as sedation or intubation [36]. Pain will be assessed
using the Numeric Rating Scale with an interrater
reliability score of κ = 0.71 [23] and the Behavioural Pain
Observation Tool which has a κ = 0.80 and a content
validity index of 0.73–1.0 [24].
Movement and movement patterns will be recorded
continuously at 100 Hz for the duration of the
participants’ stay in the ICU, with AX3 Axivity (Axivity
Ltd., Newcastle upon Tyne, UK) inertial measurement
units attached to participant’s hands, legs, and chest and
placed under the mattress (Sensing Tex, Barcelona,
Spain). To enable accurate interpretation of this data,
the participant’s environment will be recorded with a
camera. This will allow for the distinction to be made
between movements made by the participant and those
from the interprofessional team or family members. To
maximize the privacy of the participant, the camera will
be mounted on the head-end of the bed, so the face of
the participant is not visible.
Physiological parameters (e.g. non-invasive arterial
blood pressure, heart rate, and respiratory rate) will be
monitored by the in-house monitor system of the
University Hospital (GE Healthcare, Little Chalfont,
UK). Respiration and heart rate will be measured at a
frequency of 240 Hz, while the blood pressure will be
measured as the median every 2 min. A list of pharma-
cological agents provided to the participant and disease-
related data will be collected via the patient data man-
agement system. While movement and physiological
data will be recorded continuously throughout the pa-
tients’ stay in the ICU, the non-continuous assessments
will also be completed at various time points (Fig. 1).
At the earliest opportunity, the participant—or, in the
event of incapacity, his/her relatives—will be interviewed
by the study team about their health-related quality of
life, functionality, and frailty, using the EQ-5D instru-
ment [38], the Functional Independence Measure [39,
40], and the Clinical Frailty Score [41], respectively, 1
week before ICU admission and 6 months post-
discharge. The reliability and validity of the three-level
EQ-5D, the EQ-5D-3L, is well established; however, the
more recently expanded five-level version, the EQ-5D-
5L, still lacks proper reliability and validity studies [38].
The Functional Independence Measure has a reliability
score of κ > 0.85 [42, 43] and a high internal validity
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[42]. The Clinical Frailty Score has been found to have
good reliability [44] and good construct validity [41].
Cognitive impairment will be assessed by the study
team before ICU discharge and 6 months post-discharge
using the Montreal Cognitive Assessment [45]. The
Montreal Cognitive Assessment has a known reliability
of κ = 0.83 [45] and an established content validity in
English and in French [45] and a sensitivity of at least
0.90 [46]. The average survival 6 months post-discharge
will be obtained via a central database.
The study ends with a follow-up assessment 6 months
after admission to the ICU. The study team interviews
the participants during a regular follow-up session at the
ICU. During the interview, the EQ-5D-5L, Functional
Independence Measure, Clinical Frailty Score, and
Montreal Cognitive Assessment will be administered. All
assessments will be conducted according to the standard
ICU care by trained ICU nurses.
In a final step following the VR intervention, the ICU
nurse responsible for the intervention will be asked
about the feasibility of applying the intervention,
completing the 10-item System Usability Scale [29]. The
System Usability Scale has a strong reliability score κ >
0.89 [47, 48] and an established construct validity, as
well as concurrent validity (r = 0.86) [47, 48].
Plans to promote participant retention and complete
follow-up {18b}
Contact will be made with the participants after 3
months within the framework of internal quality
assurance. After that, the participant will be contacted in
writing and by telephone for the 6-month follow-up. If a
participant chooses to discontinue the study, the data
collected up to the withdrawal date will be anonymized
and used.
Data management {19}
Smaller datasets and measurements (e.g. length of ICU
stay) will be stored in the patient data management
system of the University Hospital of Bern (Inselspital).
The data will be coded by a member of the study team
using an alphanumeric system, and the identifying
information deleted from the datasets. Only the
remaining continuous data, such as physiological
measurements, movement patterns, and camera videos,
will be stored in-house on a password-protected com-
puter due to their size.
Confidentiality {27}
The data files are encrypted and will only contain a
univocal alphanumeric code, from which the identity of
the participant cannot be gathered. The key (i.e. the list
in which a code number is linked to a participant name)
will be kept separately from the study data, in a secured
cabinet, in the custody of a person who is not involved
in the study. In study-specific documents, participants
are only identified by a unique participant number.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
See above Item 26b, there will be no biological specimens
collected.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Descriptive statistics will be applied to both groups to
ensure that they similarly represent the population.
Among others, we will be looking at the mean and
standard deviation of the age, distribution of the sexes,
and frequencies of disease in the two samples.
The difference in the incidence of delirium will be
tested with the chi-square proportion test, and the dur-
ation will be tested with Welch’s t test in subgroups of
participants with delirium. The effects of the VR stimu-
lation on physiological parameters will be looked at
using statistical methods (e.g. t test, linear models). Ma-
chine learning techniques will be applied to the move-
ment patterns as means of analysis.
The data will be analysed with MATLAB and the
software R. Deviation(s) from the original statistical plan
will be granted if the collected data do not allow the
planned analysis techniques to be performed (e.g. if the
collected data does not meet the prerequisites to apply
analysis of variance techniques). In this case, more
appropriate statistical methods will be applied (e.g. non-
parametric methods), and this choice will be justified
and detailed in the respective scientific reports.
Interim analyses {21b}
A blinded interim analysis will be completed after the
inclusion of 100 participants (50 per group). A re-
estimation and adjustment of the sample size will be
made if necessary. The decision about how to proceed
following the results of the interim analysis will be made
by the independent statistician conducting the interim
analysis, together with the principal investigator.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Using data from movement patterns from a subgroup of
participants (n = 100), non-supervised machine learning
techniques will be applied to try to train a model to pre-
dict the onset of delirium. This subgroup will be used to
address the secondary objective aimed to evaluate differ-
ences in movement patterns and intensity between the
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intervention and control group and between participants
with delirium and without delirium.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
As suggested by the SPIRIT guidelines, we propose to
test superiority using two analysis sets: the “intention-to-
treat set”, considering all patients that are randomized
regardless of whether they received the randomized
treatment, and the “per protocol” set [49]. We propose
declaring superiority of the experimental intervention
only if shown superiority using both the “intention to
treat” and the “per protocol” analysis set. As our study
takes place in the ICU, it is expected that drop-outs will
occur for medical reasons which make it unfeasible to
continue in the study, but that are not related to the
study itself. For this reason, there are two groups of par-
ticipants who will be considered drop-outs. Firstly, any
participant who can no longer continue in the study due
to health reasons, before the first assessment for the
primary outcome (i.e. the ICDSC) has been completed,
will be considered a drop-out. Secondly, any participant
for whom the neutral physician gave consent, but for
whom the relatives withdrew consent, will be considered
as a drop-out. Therefore, in order to maintain a suffi-
cient sample size, it is important that these participants
are replaced in a 1:1 manner, as approved by the local
ethics committee. If a participant does drop-out of the
study, their health status will be recorded at this point.
As no long-term negative outcomes from the interven-
tion are suspected, no further follow-up will be
performed. If missing values occur within the dataset,
we will use multiple imputation assuming missing data
to be missing at random.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
We will ask patients to provide informed consent for
sharing their anonymized data. Once the study results as
outlined in this proposal are published, we will make the
de-identified study dataset available for secondary ana-
lyses by sharing the dataset upon reasonable request.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
The study will be monitored by an independent internal
monitor. The monitor will evaluate the primary and
secondary outcomes for completeness and correctness as
outlined by the study protocol. Any decisions needing to
be taken regarding the study will be done with the
consensus of the entire study team and the relevant
study authorities will be notified.
Composition of the data monitoring committee, its role,
and reporting structure {21a}
The study will be internally monitored according to the
Good Clinical Practice directive and the monitoring and
data verification plan, including the documentation of
informed consent of study participants. Internally
implies that the monitor is employed at the Department
of Intensive Care Medicine, University Hospital of Bern
(Inselspital), but carries out the monitoring independently,
as they are neither involved in the study-specific processes
(recruitment, study data collection, study interventions, or
evaluation) nor in patient care. In their employment, they
are administratively and functionally independent from
the nursing and medical sector of the department.
Adverse event reporting and harms {22}
In the scope of this study, no serious adverse events or
adverse events are expected. Due to the serious
condition of critically ill patients, adverse events will
only be reported in the medical record if they are related
to the VR intervention. Serious adverse events assessed
with a causal relationship to VR will be reported to the
ethics committee by the investigator and sponsor-
investigator within 15 days.
Frequency and plans for auditing trial conduct {23}
For quality assurance, the sponsor, the ethics committee,
or an independent intern study monitor may visit the
research site. Direct access to the source data and all
study-related files is granted on such occasions. All in-
volved parties will be required to keep the participant
data strictly confidential.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Substantial changes to the study setup and study
organization, the protocol, and relevant study
documents will be submitted to the ethics committee for
approval before implementation. Under emergency
circumstances, deviations from the protocol to protect
the rights, safety, and well-being of human subjects may
proceed without the ethics committee’s prior approval.
Such deviations shall be documented and reported to
the ethics committee as soon as possible. A list of all
non-substantial amendments will be submitted once a
year to the competent ethics committee together with
the annual safety report.
Dissemination plans {31a}
The results of the present study will be submitted for
publication in peer-reviewed journals and will be pre-
sented at national and international scientific meetings.
Currently, there are no known publication restrictions
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foreseen. The dataset will be available upon reasonable
request once results have been published.
Discussion
One challenge we will face during this study is the
unpredictable reaction of patients to the VR stimulation
when they are in a state of delirium. As such, the
feasibility of providing VR stimulation to participants
when they are already in a state of delirium is unknown.
This can specifically be a problem due to their increased
motor activity if they are in hyperactive delirium.
Furthermore, there is a risk that delirious participants
will not tolerate wearing such a head-mounted display
and headphones and may even try to remove the items
themselves. This may become a limitation in participant
recruitment, as it does occur that patients enter into a
state of delirium shortly after ICU admission. The study
team will continue to provide the stimulation for as
many days, and as consistently as possible; however, par-
ticipant safety and comfort is the priority and, therefore,
this aspect of unpredictability remains.
There currently remains the open question as to what
specific aspect of the VR may be responsible for the
effect we see, if any. Specifically, it is not known if it is
the combination of audio and visual input, or the one or
the other alone that creates an effect. Alternately, it
could be that using these devices allows the patient to
avoid noise overstimulation by using headphones and
visual overstimulation by using the headset. This
remains an open question.
It should be kept in mind that a limitation of the
current study is the sparse literature confirming the
reliability and validity of the questionnaires listed above,
specifically for use in a language other than English and
for our target group of ICU patients. The reliability and
validity of the measures listed earlier are largely based on
English speakers across a variety of patient populations
and healthy controls. Therefore, we acknowledge that
these values may not hold true, and applying it to
participants in a language other than English may result in
bias being introduced. Regarding the validity of the ICDS
C, which we use for our primary outcome, the validity for
the German version has not been assessed. Because of
this, we will cross-check the score of the ICDSC with the
Richmond Agitation Sedation Scale score. A positive
Richmond Agitation Sedation Scale score is an import-
ant indicator of delirium based on symptoms that keep
patients in the ICU, and therefore, should correspond
to the ICDSC score.
Trial status
Protocol version 2.0 (May 02, 2020)
Recruitment is expected to begin in March 2021 and
continue until March 2024.
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